A Phase II Study of Non-Myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma.

Trial Profile

A Phase II Study of Non-Myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin; Ciclosporin
  • Indications Graft-versus-host disease; Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2011 Planned End Date changed from 1 Sep 2011 to 1 Dec 2022 as reported by ClinicalTrials.gov.
    • 03 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top